A 6-Month Extension Study to B2061032 to Evaluate Desvenlafaxine Succinate Sustained-Release (DVS SR) Tablets in the Treatment of Children and Adolescent Outpatients with MDD

-
Investigator: Robert L. Hendren, DO
Sponsor: Pfizer

Location(s): United States

Description

This is a 6-month, open-label, flexible-dose study evaluating Desvenlafaxine Succinate Sustained-Release (DVS SR) in the Treatment of Child and Adolescent Outpatients with Major Depressive Disorder (MDD).